| DABP | D site albumin promoter binding protein |
|---|---|
| E* | lesion on the erythrocyte cell membrane at the site of complement fixation |
| FMR | fragile site mental retardation [syndrome]; Friend-Moloney-Rauscher [antigen] |
| fra | fragil [site] |
| FRAXE | X-linked mental retardation-fragile site [syndrome] |
| EEG activation | The low voltage, fast pattern of attentive wakefulness. (05 Mar 2000) |
|---|---|
| trans-activation (genetics) | Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.) (12 Dec 1998) |
| energy of activation | Energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction; usually expressed in the Arrhenius equation relating a rate constant to absolute temperature. (05 Mar 2000) |
| enzyme activation | Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1) activation by ions (activators); 2) activation by cofactors (coenzymes); and 3) conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. (12 Dec 1998) |
| juxtacrine activation | Activation of target cells by membrane anchored growth factors, also used for activation of leucocytes by PAF bound to endothelial cell surface. (18 Nov 1997) |
| feedback activation | The activation of an enzyme by an end product of a biochemical pathway in which that enzyme plays a part. For example, the activation of factors VIII and V by thrombin during blood clotting. (05 Mar 2000) |
| feed-forward activation | The activation of an enzyme by a precursor of the substrate of that enzyme. (05 Mar 2000) |
| low-activation materials | <radiobiology> In fission reactors, one is forced to deal with the radioactive byproducts of the fission process, but in fusion reactors one generally has a choice of what materials to expose to neutrons produced by the fusion process. A major problem for fusion reactors is developing materials (such as for the reactor vacuum vessel structure) which can be exposed to high levels of neutron bombardment without becoming permanently radioactive. Candidate structural materials which have relatively low induced radiactivation (generally relative to stainless steel) are known as low-activation materials, these include titanium, vanadium, and silicon-carbide. (09 Oct 1997) |
| lymphocyte activation | <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term. (18 Nov 1997) |
| acceptor site | The ribosomal binding site for the aminoacyl-tRNA during protein synthesis. (05 Mar 2000) |
| acceptor splicing site | Boundary between the right end of an intron and the left end of the adjacent exon. Synonym: acceptor splicing site. (05 Mar 2000) |
| active site | <chemistry> A specific region of an enzyme where a substrate binds and catalysis takes place (binding site). (06 May 1997) |
| allosteric site | A specific site on a multi-subunit enzyme or other protein that is not the substrate binding site, but that when reversibly bound by an effector, induces a conformational change in the protein, altering its catalytic or binding properties. (12 Dec 1998) |
| amidation site | <molecular biology> A C terminus consensus sequence, required for C terminus amidation of peptides. Consensus is glycine, followed by 2 basic amino acids (arg or lys). (18 Nov 1997) |
| antibody combining site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |